Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) – Investment analysts at Leerink Swann boosted their Q3 2017 earnings estimates for shares of Ionis Pharmaceuticals in a report issued on Wednesday, Zacks Investment Research reports. Leerink Swann analyst P. Matteis now forecasts that the company will earn $0.07 per share for the quarter, up from their prior estimate of $0.06. Leerink Swann also issued estimates for Ionis Pharmaceuticals’ Q4 2017 earnings at $0.05 EPS, FY2017 earnings at $0.05 EPS and FY2018 earnings at ($0.85) EPS.
TRADEMARK VIOLATION NOTICE: This story was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2017/11/13/leerink-swann-comments-on-ionis-pharmaceuticals-inc-s-q3-2017-earnings-ions.html.
Several other equities research analysts have also recently weighed in on IONS. BMO Capital Markets reissued an “outperform” rating and set a $62.00 price objective (up from $59.56) on shares of Ionis Pharmaceuticals in a research note on Tuesday, July 25th. Needham & Company LLC reaffirmed a “buy” rating and set a $64.00 target price on shares of Ionis Pharmaceuticals in a research note on Wednesday, July 26th. Sanford C. Bernstein began coverage on Ionis Pharmaceuticals in a research note on Thursday, July 27th. They set a “market perform” rating and a $57.00 target price on the stock. Zacks Investment Research cut Ionis Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 28th. Finally, Stifel Nicolaus upped their target price on Ionis Pharmaceuticals from $42.00 to $50.00 and gave the company a “hold” rating in a research note on Wednesday, August 9th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and six have given a buy rating to the company’s stock. Ionis Pharmaceuticals has an average rating of “Hold” and an average target price of $50.31.
Shares of Ionis Pharmaceuticals (NASDAQ:IONS) traded up $0.76 during midday trading on Friday, reaching $55.88. The company’s stock had a trading volume of 699,400 shares, compared to its average volume of 1,512,485. The company has a quick ratio of 6.21, a current ratio of 6.25 and a debt-to-equity ratio of 1.50. Ionis Pharmaceuticals has a 52 week low of $37.26 and a 52 week high of $65.51. The company has a market capitalization of $6,973.57, a PE ratio of 372.53 and a beta of 2.90.
Institutional investors have recently bought and sold shares of the business. Parallel Advisors LLC lifted its holdings in Ionis Pharmaceuticals by 62.8% during the second quarter. Parallel Advisors LLC now owns 2,073 shares of the company’s stock worth $109,000 after buying an additional 800 shares during the period. Hanseatic Management Services Inc. lifted its holdings in Ionis Pharmaceuticals by 1.2% during the second quarter. Hanseatic Management Services Inc. now owns 3,481 shares of the company’s stock worth $177,000 after buying an additional 41 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in Ionis Pharmaceuticals by 9.1% during the second quarter. The Manufacturers Life Insurance Company now owns 3,744 shares of the company’s stock worth $190,000 after buying an additional 311 shares during the period. WFG Advisors LP lifted its holdings in Ionis Pharmaceuticals by 77.2% during the second quarter. WFG Advisors LP now owns 3,800 shares of the company’s stock worth $193,000 after buying an additional 1,655 shares during the period. Finally, CIBC Asset Management Inc purchased a new stake in Ionis Pharmaceuticals during the third quarter worth $212,000. Institutional investors own 88.98% of the company’s stock.
In other Ionis Pharmaceuticals news, COO B Lynne Parshall sold 16,118 shares of the company’s stock in a transaction on Wednesday, October 18th. The stock was sold at an average price of $65.00, for a total transaction of $1,047,670.00. Following the completion of the sale, the chief operating officer now owns 33,526 shares in the company, valued at $2,179,190. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Chairman Stanley T. Crooke sold 27,500 shares of the company’s stock in a transaction on Wednesday, October 4th. The stock was sold at an average price of $52.89, for a total value of $1,454,475.00. The disclosure for this sale can be found here. Insiders sold 98,636 shares of company stock valued at $5,723,915 in the last quarter. 2.13% of the stock is owned by company insiders.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
Get a free copy of the Zacks research report on Ionis Pharmaceuticals (IONS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.